← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Chicago Biosolutions, Inc.
Chicago, IL
$8,762,050
Total funding
7
Grants
Funding over time
peak $1.6M · FY2016–24$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,537,050 · 6
CDC$225,000 · 1
By mechanism
R42$6,214,495 · 2
R41$2,322,555 · 4
R43$225,000 · 1
Investigators at Chicago Biosolutions, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics$999,369
R42 · FY2022 · AI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics$999,369
R42 · FY2023 · AI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics$999,234
R42 · FY2024 · AI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$982,388
R42 · FY2021 · AI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$972,475
R42 · FY2019 · AI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$961,660
R42 · FY2020 · AI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$363,601
R41 · FY2016 · AI
4-(Aminomethyl) benzamides as novel anti-Ebola agents$363,598
R41 · FY2017 · AI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics$300,000
R42 · FY2021 · AI
Development of group 2 influenza A virus entry inhibitors$299,999
R41 · FY2019 · AI
Development of group 2 influenza A virus entry inhibitors$299,999
R41 · FY2020 · AI
Furopyrimidines as novel inhibitors of henipaviruses$299,667
R41 · FY2022 · AI
Furopyrimidines as novel inhibitors of henipaviruses$299,595
R41 · FY2021 · AI
4-Aminopiperidines as novel anti-influenza agents$242,913
R41 · FY2016 · AI
Furopyrroles as Novel anti-Ebola Agents$225,000
R43 · FY2016 · CK
4-Aminopiperidines as novel anti-influenza agents$153,183
R41 · FY2017 · AI